Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease

Area of Science:

• Hepatology
• Pharmacology
• Metabolic Diseases

Background:

• Non-alcoholic fatty liver disease (NAFLD) is the leading cause of chronic liver disease globally.
• NAFLD is frequently linked to metabolic conditions like obesity, diabetes, hypertension, and dyslipidemia.
• Non-alcoholic steatohepatitis (NASH), a severe form of NAFLD, significantly elevates mortality risk.

Purpose of the Study:

• To provide a comprehensive overview of current clinical trials for emerging NAFLD/NASH therapies.
• To review novel drug candidates targeting the underlying mechanisms of NAFLD/NASH.
• To highlight the therapeutic pipeline addressing a critical unmet medical need.

Main Methods:

• Systematic review of ongoing clinical trials for NAFLD/NASH treatments.
• Analysis of drug development strategies focusing on pathogenic pathways.
• Literature search for emerging therapeutic agents and their mechanisms of action.

Main Results:

• Several novel agents targeting lipid metabolism, inflammation, and fibrosis are in various phases of clinical trials.
• Drug development is actively exploring diverse mechanisms to combat NAFLD/NASH progression.
• The pipeline includes multiple promising candidates, indicating significant research investment.

Conclusions:

• There is a pressing need for effective NAFLD/NASH therapies due to the inadequacy of current treatments.
• Emerging drug candidates show potential to address the unmet medical need in NAFLD/NASH.
• The reviewed trials and agents represent the forefront of therapeutic innovation for these liver conditions.